In experimental settings, CB1 agonists like THC do alter sleep architecture, shifting NREM and REM balance and restructuring intermediate sleep stages.
The BNY Mellon Small Cap Value Fund underperformed its benchmark in Q4 2025 despite gains in technology. Read the full analysis for more details.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results